Pharmaceuticals · Nasdaq
VTRSViatris Inc
- Last close
- $20.82 +0.7%
- 52-week range
- $10.15 to $21.20
- Market cap
- $23.9B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own history since 2020
Above its median since 2020 on all 3 multiples
Where each multiple sits today inside its own range since 2020, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- n/aNo earnings
- Earnings yield
- n/aNot reported
- Price / sales
- 1.6x
- Price / book
- 1.7x
- Price / operating cash flow
- 9.6x
- EV / EBITDA
- 12.6x
- EV / sales
- 2.4x
- Free cash flow yield
- 8.8%
Profitability
- Gross margin
- 35.4%
- Operating margin
- -0.03%
- Net margin
- -4.1%
- Return on equity
- -4.4%
- Return on capital
- -0.01%
Growth per year
- Revenue, 3 years
- -4.2%
- Revenue, 5 years
- +3.8%
- Revenue, 7 years
- +3.4%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $1.79B
- Total debt
- $13.3B
- Net cash
- -$11.5B
- Debt / equity
- 0.97x
- Current ratio
- 1.55x
Shares and dividend
- Shares outstanding
- 1.15B
- Share count, 5 years
- +134%
- Beta, 1 year
- 0.64
- Dividend yield
- 2.3%
- Dividend per share, TTM
- $0.48
- Payout ratio
- n/aNot meaningful
Every year we have of the business
Last 29 quarters, fiscal 2018 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2018 to 2025.
Where the revenue comes from
Brands went from 61% to 64% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Brands | $9.18B | 64.2% | -0% |
| Lipitor | $1.55B | 10.8% | n/a |
| Norvasc | $710M | 5.0% | n/a |
| Lyrica | $487M | 3.4% | n/a |
| Epi Pen Auto Injectors | $470M | 3.3% | n/a |
| Viagra | $408M | 2.9% | n/a |
| Other | $1.42B | 9.9% | n/a |
Pharmaceuticals peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| LLY ELI LILLY & Co | $1.36T | +46% | n/a | 46.8x | 15.7x | 60th percentile |
| JNJ Johnson & Johnson | $688B | +8% | n/a | 43.4x | 6.9x | 90th percentile |
| MRK Merck & Co., Inc. | $364B | +5% | n/a | 152x | 5.4x | 98th percentile |
| PFE Pfizer Inc | $165B | +1% | n/a | 41.2x | 2.6x | 97th percentile |
| BMY Bristol Myers Squibb Co | $130B | +4% | n/a | 14.1x | 2.6x | 13th percentile |
| VTRS Viatris Inc | $23.9B | +4% | -0.03% | No earnings | 1.6x | No earnings |
The company
- Sector
- Health Care
- Industry
- Pharmaceuticals
- CEO
- Scott A. Smith
- Founded
- 2020
- Headquarters
- Canonsburg, PA
- Fiscal year ends
- December
- Website
- viatris.com/en
What it does
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about VTRS.